Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Background: Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities. Methods: In sunitinib-treated mRCC patients ( N =770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ⩾140 mm Hg),...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2015-12, Vol.113 (11), p.1571-1580
Main Authors: Donskov, Frede, Michaelson, M Dror, Puzanov, Igor, Davis, Mellar P, Bjarnason, Georg A, Motzer, Robert J, Goldstein, David, Lin, Xun, Cohen, Darrel P, Wiltshire, Robin, Rini, Brian I
Format: Article
Language:English
Subjects:
692/699/67/1059/99
692/699/67/1857
692/699/67/589/1588/1351
692/699/75/243
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - secondary
Disease-Free Survival
Drug Resistance
Epidemiology
Fatigue - chemically induced
Female
Hand-Foot Syndrome - etiology
Humans
Hypertension - chemically induced
Indoles - adverse effects
Indoles - therapeutic use
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Male
Middle Aged
Molecular Medicine
Neutropenia - chemically induced
Oncology
Pyrroles - adverse effects
Pyrroles - therapeutic use
Sunitinib
Survival Rate
Translational Therapeutics
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities. Methods: In sunitinib-treated mRCC patients ( N =770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ⩾140 mm Hg), neutropenia (grade ⩾2), thrombocytopenia (grade ⩾2), hand–foot syndrome (grade >0), and asthenia/fatigue (grade >0)) were analysed in multivariate analyses of progression-free survival (PFS) and overall survival (OS) end points. Results: On-treatment neutropenia and hypertension were associated with longer PFS ( P =0.0276 and P
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2015.368